SG11202101099PA - Afucosylated antibodies and manufacture thereof - Google Patents
Afucosylated antibodies and manufacture thereofInfo
- Publication number
- SG11202101099PA SG11202101099PA SG11202101099PA SG11202101099PA SG11202101099PA SG 11202101099P A SG11202101099P A SG 11202101099PA SG 11202101099P A SG11202101099P A SG 11202101099PA SG 11202101099P A SG11202101099P A SG 11202101099PA SG 11202101099P A SG11202101099P A SG 11202101099PA
- Authority
- SG
- Singapore
- Prior art keywords
- manufacture
- afucosylated antibodies
- afucosylated
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01047—GDP-mannose 4,6-dehydratase (4.2.1.47), i.e. GMD
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01068—Glycoprotein 6-alpha-L-fucosyltransferase (2.4.1.68), i.e. FUT8
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/102995 WO2020042015A1 (en) | 2018-08-29 | 2018-08-29 | Afucosylated antibodies and manufacture thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202101099PA true SG11202101099PA (en) | 2021-03-30 |
Family
ID=69642839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101099PA SG11202101099PA (en) | 2018-08-29 | 2018-08-29 | Afucosylated antibodies and manufacture thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210317499A1 (sv) |
EP (1) | EP3818149A4 (sv) |
JP (1) | JP7216806B2 (sv) |
KR (1) | KR102596303B1 (sv) |
CN (1) | CN113166728A (sv) |
AU (1) | AU2018438767B9 (sv) |
BR (1) | BR112021003765A2 (sv) |
CA (1) | CA3110254C (sv) |
MY (1) | MY197429A (sv) |
SG (1) | SG11202101099PA (sv) |
WO (1) | WO2020042015A1 (sv) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018438163A1 (en) * | 2018-08-29 | 2021-04-01 | United Biopharma Inc | Afucosylated antibodies and manufacture thereof |
AU2022289365A1 (en) | 2021-06-07 | 2023-12-14 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
CN113684322B (zh) * | 2021-09-09 | 2024-01-23 | 上海药明生物技术有限公司 | 一种降低抗体类蛋白高聚甘露糖型水平的方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA013224B1 (ru) * | 2000-10-06 | 2010-04-30 | Киова Хакко Кирин Ко., Лтд. | Клетки, продуцирующие композиции антител |
PL373256A1 (en) * | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
EP1888638A2 (en) * | 2005-06-03 | 2008-02-20 | Genentech, Inc. | Method of producing antibodies with modified fucosylation level |
WO2008090958A1 (ja) * | 2007-01-24 | 2008-07-31 | Kyowa Hakko Kirin Co., Ltd. | ドメイン交換された遺伝子組換え抗体組成物 |
DK2438171T3 (en) * | 2009-06-02 | 2015-01-26 | Regeneron Pharma | Fucosylerings-deficient cells |
US8469819B2 (en) * | 2009-06-04 | 2013-06-25 | Michael Parker McMain | Game apparatus and game control method for controlling and representing magical ability and power of a player character in an action power control program |
CA2791652C (en) * | 2010-03-02 | 2018-06-12 | Kyowa Hakko Kirin Co., Ltd. | Modified antibody composition |
IL217216A0 (en) * | 2011-12-27 | 2012-07-31 | Merck Serono Sa | Low fucose cell lins and uses thereof |
US9574003B2 (en) * | 2011-03-06 | 2017-02-21 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
US10077434B2 (en) * | 2014-07-30 | 2018-09-18 | Zumutor Biologics Inc. | Non-fucosylated protein and methods thereof |
MX2018004831A (es) * | 2015-11-02 | 2018-08-01 | Genentech Inc | Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina. |
CN106167525B (zh) * | 2016-04-01 | 2019-03-19 | 北京康明百奥新药研发有限公司 | 筛选超低岩藻糖细胞系的方法和应用 |
CN106701823A (zh) * | 2017-01-18 | 2017-05-24 | 上海交通大学 | 生产无岩藻糖单克隆抗体的cho细胞系建立及其应用 |
CN107881160A (zh) * | 2017-08-11 | 2018-04-06 | 百奥泰生物科技(广州)有限公司 | 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法 |
-
2018
- 2018-08-29 CN CN201880096956.2A patent/CN113166728A/zh active Pending
- 2018-08-29 KR KR1020217007804A patent/KR102596303B1/ko active IP Right Grant
- 2018-08-29 CA CA3110254A patent/CA3110254C/en active Active
- 2018-08-29 US US17/270,987 patent/US20210317499A1/en active Pending
- 2018-08-29 SG SG11202101099PA patent/SG11202101099PA/en unknown
- 2018-08-29 AU AU2018438767A patent/AU2018438767B9/en active Active
- 2018-08-29 JP JP2021511628A patent/JP7216806B2/ja active Active
- 2018-08-29 MY MYPI2021000708A patent/MY197429A/en unknown
- 2018-08-29 EP EP18931397.6A patent/EP3818149A4/en active Pending
- 2018-08-29 WO PCT/CN2018/102995 patent/WO2020042015A1/en unknown
- 2018-08-29 BR BR112021003765-9A patent/BR112021003765A2/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2018438767A1 (en) | 2021-04-01 |
MY197429A (en) | 2023-06-16 |
JP2021534801A (ja) | 2021-12-16 |
JP7216806B2 (ja) | 2023-02-01 |
EP3818149A1 (en) | 2021-05-12 |
CA3110254A1 (en) | 2020-03-05 |
US20210317499A1 (en) | 2021-10-14 |
CA3110254C (en) | 2023-08-29 |
AU2018438767B9 (en) | 2023-10-05 |
EP3818149A4 (en) | 2022-03-23 |
WO2020042015A1 (en) | 2020-03-05 |
AU2018438767B1 (sv) | 2023-07-13 |
CN113166728A (zh) | 2021-07-23 |
BR112021003765A2 (pt) | 2021-05-25 |
KR20210047316A (ko) | 2021-04-29 |
KR102596303B1 (ko) | 2023-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276950A (en) | Anti-CD73 antibodies and uses thereof | |
IL275737A (en) | Variant antibodies against TIGIT | |
IL282968A (en) | Anti-NKG2A antibodies and their use | |
SG11202105885WA (en) | Anti-claudin antibodies and uses thereof | |
IL275826A (en) | Anti-mct1 antibodies and their uses | |
SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
IL289585A (en) | DLL3-targeted antibodies and uses thereof | |
IL281297A (en) | Anti-NPR1 antibodies and uses thereof | |
IL277330A (en) | Anti-IL-27 antibodies and uses thereof | |
SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
SG11202112112UA (en) | Anti-galectin-9 antibodies and uses thereof | |
IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
IL280321A (en) | Antibodies against CXCR2 and their uses | |
IL281202A (en) | Anti-TNFRSF9 antibodies and uses thereof | |
IL277075A (en) | Anti-PHF-tau antibodies and uses thereof | |
IL276548A (en) | Binding antibodies - BCMA and their uses | |
SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
GB201712032D0 (en) | Antibodies and uses thereof | |
IL283926A (en) | Antibodies against alpha-synuclein and their uses | |
IL291550A (en) | Anti-il-27 antibodies and their uses | |
IL291546A (en) | Antibodies against kir3dl3 and their uses | |
SG11202101099PA (en) | Afucosylated antibodies and manufacture thereof | |
IL291280A (en) | Antibodies against cd371 and their uses | |
AU2018438767B2 (en) | Afucosylated antibodies and manufacture thereof |